Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: RM-018
  • Price: $Inquiry/100mg ¥Inquiry/250mg ¥Inquiry/1g
  • Purity: 98.0%
  • Stocking Period: 1 Day
  • Contact: Tony Cao

2641993-55-5

2641993-55-5 structure
2641993-55-5 structure
  • Name: RM-018
  • Chemical Name: RM-018
  • CAS Number: 2641993-55-5
  • Molecular Formula: C56H72N8O8
  • Molecular Weight: 985.22
  • Catalog: Signaling Pathways GPCR/G Protein Ras
  • Create Date: 2022-01-19 18:12:15
  • Modify Date: 2024-01-11 17:52:39
  • RM-018 is a potent, functionally distinct tricomplex KRASG12C active-state inhibitor. RM-018 retaines the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active [“RAS(ON)”] state of KRASG12C[1].

Name RM-018
Description RM-018 is a potent, functionally distinct tricomplex KRASG12C active-state inhibitor. RM-018 retaines the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active [“RAS(ON)”] state of KRASG12C[1].
Related Catalog
Target

KRAS(G12C)

KRAS(G12C/Y96D)

In Vitro RM-018 is a “tricomplex” KRAS inhibitor, which exploits a highly abundant chaperone protein, cyclophilin A, to bind and inhibit KRASG12C[1] .RM-018 (0.01-1000 nM; 72 hours) has an IC50 of 1.4-3.5 nM (KRASG12C) and 2.8-7.3 nM (KRASG12C/Y96D) in NCI-H358, MIA PaCa-2, Ba/F3, and MGH1138-1 cells[1]. RM-018 (0-100 nM; 4 hours) inhibits the expression of KRAS, pERK and pRSK protein[1]. Cell Viability Assay[1] Cell Line: NCI-H358, MIA PaCa-2, Ba/F3, and MGH1138-1 cells, which stably infected with KRASG12C or KRASG12C/Y96D. Concentration: 0.01-1000 nM Incubation Time: 72 hours Result: Inhibited the cell activity, but largely unaffected by KRASG12C/Y96D expression. Western Blot Analysis[1] Cell Line: MIA PaCa-2, HEK293T and MGH1138-1 cells, which expressing KRASG12C or KRASG12C/Y96D. Concentration: 0-100 nM Incubation Time: 4 hours Result: Inhibited KRAS, pERK and pRSK levels with similar potency.
References

[1]. [1] Tanaka N, et.al. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021 Aug;11(8):1913-1922.

Molecular Formula C56H72N8O8
Molecular Weight 985.22